albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-24. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
== Mechanism of action == The osmotic activity of icodextrin keeps the solution inside the peritoneum for three to four days, separating tissues and thus reducing adhesion between them when fibrin is formed after a surgery. In other words, the tissues are kept from gluing together.
== Pharmacokinetics == Maximum decrease in blood pressure occurs 4–6 hours after oral dosage. The half-life of methyldopa is 105 minutes. Methyldopa exhibits variable absorption from the gastrointestinal tract. It is metabolized in the liver and intestines and is excreted in urine.
== Transplantation and gene therapy == Hematopoietic stem cells (HSC) are cells in the bone marrow that can develop into all types of blood cells, including red blood cells, white blood cells, and platelets. There are two possible ways to treat hemoglobinopathies by targeting HSCs. One is to transplant HSCs from a healthy donor into the patient's bone marrow; this was pioneered in 1981. More recently, it has become possible to use CRISPR gene editing technology to modify the patient's own HSCs in a way that increases production of functional beta-globin chains, leading to near normal levels of healthy hemoglobin. All stem cell treatments must involve myeloablation of the patients' bone marrow in order to remove HSCs containing the faulty gene. This requires high doses of chemotherapy agents with side effects such as sickness and tiredness. A long hospital stay is necessary after infusion of the replacement HSCs while the cells take up residence in the bone marrow and start to make red blood cells with the stable form of haemoglobin.
== Chemistry == Bicalutamide is a racemic mixture consisting of equal proportions of enantiomers (R)-bicalutamide (dextrorotatory) and (S)-bicalutamide (levorotatory). Its systematic name (IUPAC) is (RS)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide. The compound has a chemical formula of C18H14F4N2O4S, a molecular weight of 430.373 g/mol, and is a fine white to off-white powder. The acid dissociation constant (pKa') of bicalutamide is approximately 12. It is a highly lipophilic compound (log P = 2.92). At 37 °C (98.6 °F), or normal human body temperature, bicalutamide is practically insoluble in water (4.6 mg/L), acid (4.6 mg/L at pH 1), and alkali (3.7 mg/L at pH 8). In organic solvents, it is slightly soluble in chloroform and absolute ethanol, sparingly soluble in methanol, and freely soluble in acetone and tetrahydrofuran. Bicalutamide is a synthetic and nonsteroidal compound which was derived from flutamide. It is a bicyclic compound (has two rings) and can be classified as and has variously been referred to as an anilide (N-phenylamide) or aniline, a diarylpropionamide, and a toluidide. The crystalline structure of bicalutamide is represented by a wide variety of conformation-dependent solid forms, including polymorphs, crystal solvates, co-crystals, and others. The formation and stabilization of these solid forms are largely governed by the solvent environment, which influences the conformational preferences of bicalutamide molecules as well as the intermolecular interactions established during crystallization.
Sources: en.wikipedia.org
== Effects of MPPT on wound healing == MPPT has been evaluated in a preclincial wound healing model and in a 266 patient comparative clinical study, which included a wide range of wound types. The study found that MPPT reduced the time to achieving an infection-free and healing wound by 60% compared to a topical antibiotic (genamicin) and to the antiseptic iodine. MPPT also reduced the number of hospitalisation days by 31% compared to the antibiotic. At Bristol University Hospital, MPPT was evaluated for use on wounds. The study included nine dehisced surgical wounds and one category 4 pressure ulcer. Standard-of-care for these types of wounds are one week with UrgoClean followed by 2 or more weeks with Negative Pressure Wound Therapy (NPWT). Wounds receiving MPPT were able to achieve the same stage of wound healing in 4–5 days as would have required 3 or more weeks with standard-of-care, thus offering savings of 67%. All wounds receiving MPPT closed. MPPT has also been used on diabetic foot ulcers and venous leg ulcers, including ulcers that were chronic and non-healing and in all cases it has been able to promote healing. MPPT has also been used on pressure ulcers, including chronic non-healing ulcers and was in a similar manner able to promote healing. A poster was recently presented by the Birmingham University Hospitals at the British Association of Dermatologists, which showed that MPPT was able to assist the healing of 3 chronic, stable pyoderma gangrenosum ulcers. In one patient, it was possible to reduce the dose of immunosuppressant.
Mary Brown's operated mainly in Newfoundland (about 20 locations with 2 locations in Halifax and 1 in Ontario) until the late 1970s, when it began expanding in Ontario, Alberta and Nova Scotia. In 2010, there were 38 locations in Newfoundland and Labrador, 30 locations in Ontario, 12 in Alberta and 3 in Nova Scotia, for an approximate total of 83. As of 2017, Mary Brown's has expanded into the United States, specifically in Florida. Drive-through and delivery services are available at some locations. The restaurant chain, started by Newfoundlanders Pat Tarrant and Cyril Fleming in 1969, was named after Mary Brown, the wife of a fried chicken recipe creator. The headquarters are in Markham, Ontario.
=== Derivatives === Various alginate-based materials can be produced, including porous scaffold material, alginate hydrogel, nonwoven fabric, and alginate membranes. Techniques used to produce these include ion cross-linking, microfluidic spinning, freeze drying, wet spinning, and immersive centrifugal jet spinning. Calcium salts added to a sodium alginate solution to induce ionic cross-linking, which produces the hydrogel. Freeze-drying the hydrogel to eliminate water produces the porous scaffold material. Wet spinning consists of extruding an alginate solution from a spinneret into a calcium salt solution to induce ionic cross-linking (forming the gel), and then drawing the fibers out of the bath with draft rollers. Microfluidic spinning, a simpler and more eco-friendly implementation of the process, involves introducing calcium salt flows flowing alongside and touching a central "core" flow of alginate. These flows form a "sheath". The fiber then emerges from the core flow. This technique can be used to produce shaped and grooved fibers.
Sources: en.wikipedia.org
=== Mitigate carbon nanotube toxicity via physicochemical modulation === Length, diameter, and aggregation state: As-synthesized CNTs typically form large bundles or agglomerates, which are associated with increased cytotoxicity. Disaggregation into individualized CNTs and cutting length can mitigate toxicity. These modifications are commonly achieved through tip ultrasonication in the presence of surfactants or polymers, followed by ultracentrifugation to remove residual bundles and impurities. Such processing enhances dispersion, reduces rigidity, and improves biocompatibility. Single-type enrichment and classification: Heterogeneity in CNT materials contributes to inconsistent biological responses. Advanced sorting techniques, such as aqueous two-phase extraction, size-exclusion chromatography, and density gradient ultracentrifugation, can sort CNTs by specific parameters such as diameter, length, number of walls, and chirality. Purity enhancement: Post-synthesis purification techniques—such as mild oxidation, sonication in hydrogen peroxide or acetone, acid washing, and incandescent annealing—are employed to remove residual metal catalysts and carbonaceous byproducts. Surface modification: Non-covalent modification: Wrapping CNTs with biocompatible polymers such as single-stranded DNA (ssDNA), phospholipid–polyethylene glycol, or Pluronic F108 enhances solubility, colloidal stability, and biological compatibility without altering the intrinsic structure of the nanotubes.
Stephanie Kate Howard, Moves and Operations Manager, Buckingham Palace Re-servicing Programme, Royal Household. Adelaide Georgina Gray Izat, Paintings Conservator, Royal Collection, Royal Household. Daniel James Kevin Johnson, Archbishop of Canterbury's Coronation Planning Director, on the occasion of the Coronation of Their Majesties The King and The Queen. Kevin Malkin, Detective Constable, Metropolitan Police Service. For services to Royalty Protection. Louise Michelle Walker-Pickett, Purchasing and Cost Control Co- ordinator, Royal Household. Nicola Jane Pritchard, Property Project Manager, Windsor Castle. Warrant Officer Class 1 David Alexander Roper, Grenadier Guards, 25131200; Superintending Clerk, Household Division, on the occasion of the Coronation of Their Majesties The King and The Queen. Warrant Officer Class 2 Julian Philip Desmond Sandford, Royal Corps of Army Music, 25152991; Sergeant Major, Band of the Household Cavalry, on the occasion of the Coronation of Their Majesties The King and The Queen. Christopher Charles Savage, lately Messenger Sergeant Major, The King's Body Guard of the Yeomen of the Guard. Derrick Andrew Scott, Royal Borough of Windsor and Maidenhead, on the occasion of the Coronation Concert. Thomas Nicholas McKinlay Service, lately Acting Chief Operating Officer, Household of The Prince and Princess of Wales. Elizabeth Fiona St Clair, Sergeant, Metropolitan Police Service. For services to Royalty and Specialist Protection. Kathryn Elizabeth Stone, Paper Conservator, Royal Collection, Royal Household.
== Budget == For the 2026 fiscal year, CLIA was budgeted US$25.2 million. The approximately 86 surveyors conduct 120 surveys annually, 112 initial/recertification and eight follow-up surveys, spending an average of up to 14 hours per survey. The staffing ratio is one clerk per three surveyors, one professional support staff per six surveyors, and one supervisory surveyor per seven surveyors. The projected workload is 7,933 compliance initial and recertification surveys, 2505 follow-up/revisit surveys of compliance laboratories, 393 validations of accredited laboratories, 92 follow-up/revisit surveys of accredited laboratories, 215 complaint surveys, and 725 proficiency testing desk reviews. The Waived Laboratory Survey Initiative is discontinued, and CLIA waivers are no longer available; PPM laboratories will not receive routine inspections.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.